Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (12)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Pierga, J. Y.
Right arrow Articles by Pouillart, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pierga, J. Y.
Right arrow Articles by Pouillart, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 12:231-237, 2001
© 2001 European Society for Medical Oncology

research-article

Response to chemotherapy is a major parameter-influencing long-term survival of metastatic breast cancer patients

J. Y. Pierga1,, M. Robain2, M. Jouve1, B. Asselain2, V. Diéras1, P. Beuzeboc1, T. Palangié1, T. Dorval1, J.-M. Extra1, S. Scholl1 and P. Pouillart1

1Medical Oncology Department
2Biostatistics Department, Institut Curie. Paris. France

Dr J.-Y. Pierga Département d'Oncologie Médicale Institut Curie, 26 rue d'Ulm 75231 Paris Cedex 05 Francejean-Yves.Pierga{at}curie.net

BACKGROUND:: In cancer patients, correlation between response to chemotherapy and gain in survival remains debated. We addressed this question in a multivariate analysis evaluating response to chemotherapy as a factor influencing survival of patients with metastatic breast cancer.

PATIENTS AND METHODS:: From 1977 to 1992, 1430 patients included in eight consecutive prospective trials of anthracycline based first-line chemotherapy in metastatic breast cancer, were available for assessment. Median follow-up was 155 months.

RESULTS:: Median survival from the date of randomisation was 24 months. Objective response rate was 63.6%. A complete response (CR) was achieved in 17% (249 patients). In a stepwise forward progression analysis objective response was the first independent prognostic factor for survival. Median survival time was 43 months for complete responders (CR). 29 months for partial responders (PR), 18 months for stable disease (SD), 5 months for progressive disease (PD). The probability of survival at 5 and 10 years was 35% and 15% for CR's and decreased to 18% and 6% for PR's. The timing of best response (at 4 or 8 months) was not related to outcome.

CONCLUSIONS:: Response to an anthracycline-based chemotherapy is a major independent prognostic factor in metastatic breast cancer. The use of this factor to investigate new drugs seems to be pertinent. The good prognosis of complete responders justifies further evaluation of new treatment strategies for this patient population.

chemotherapy, metastatic breast cancer, prognostic factors


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 The OncologistHome page
J. O'Shaughnessy
Extending Survival with Chemotherapy in Metastatic Breast Cancer
Oncologist, October 1, 2005; 10(suppl_3): 20 - 29.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Bruzzi, L. Del Mastro, M. P. Sormani, L. Bastholt, M. Danova, C. Focan, G. Fountzilas, J. Paul, R. Rosso, and M. Venturini
Objective Response to Chemotherapy As a Potential Surrogate End Point of Survival in Metastatic Breast Cancer Patients
J. Clin. Oncol., August 1, 2005; 23(22): 5117 - 5125.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. J. Epstein
Maintenance Therapy to Suppress Micrometastasis: The New Challenge for Adjuvant Cancer Treatment
Clin. Cancer Res., August 1, 2005; 11(15): 5337 - 5341.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
P. Noordhuis, U. Holwerda, C. L. Van der Wilt, C. J. Van Groeningen, K. Smid, S. Meijer, H. M. Pinedo, and G. J. Peters
5-Fluorouracil incorporation into RNA and DNA in relation to thymidylate synthase inhibition of human colorectal cancers
Ann. Onc., July 1, 2004; 15(7): 1025 - 1032.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.